Table 1.
Study Characteristics of Rectal and Anal Cancer by Sex, Race, Age and Tumor Stage, CDC CRSSS, 2014–2015
| Rectala (n = 39) |
Analb (n = 72) |
||||
|---|---|---|---|---|---|
| Characteristics | n | %c | n | %c | P Valued |
| Sex | .08 | ||||
| Male | 20 | 50.8 | 29 | 29.9 | |
| Female | 19 | 49.2 | 43 | 70.1 | |
| Race | .53 | ||||
| White | 34 | 88.3 | 57 | 91.2 | |
| Black | 5 | 11.7 | 15 | 8.8 | |
| Age (y) | .34 | ||||
| 30–39 | 3 | 7.3 | 9 | 3.4 | |
| 40–49 | 7 | 17.6 | 28 | 13.7 | |
| 50–59 | 5 | 11.7 | 14 | 25.4 | |
| ≥60 | 24 | 63.5 | 21 | 57.5 | |
| Stagee | .25 | ||||
| Early | 14 | 37 | 36 | 45.7 | |
| Late | 21 | 52.9 | 33 | 51.5 | |
| Unknown | 4 | 10.1 | 3 | 2.7 | |
CDC, Centers for Disease Control and Prevention; CRSSS, Cancer Registry Sentinel Surveillance System; HPV, human papillomavirus.
Rectal cancer includes ICD-O-3 site code C20.9 and morphology codes 8050–8084 and 8120–8131.
Anal cancer includes ICD-O-3 site codes C21.0–C21.8; morphology codes 8720–8790 (melanoma), 8800–8991 (sarcoma), 9050–9055 (mesothelioma), 9140 (Kaposi sarcoma), and 9590–9992 (leukemias/lymphomas) were excluded.
Weighted percentages take into account sampling frame for age and race/ethnicity.
Statistical testing performed with first order Rao-Scott χ2 statistics with α = .05.
Surveillance, Epidemiology, and End Results (SEER) summary stage, early stage includes localized cancers, late stage includes regional and distanct cancers.